| Literature DB >> 33715927 |
Denise Utami Putri1, Yi-San Tsai2, Jin-Hua Chen3, Ching-Wen Tsai4, Chung-Yi Ou5, Chiao-Ru Chang6, Hui-Chun Chen6, Mong-Liang Lu7, Ming-Chih Yu8, Chih-Hsin Lee9.
Abstract
BACKGROUND: Global pandemic resulted from the coronavirus disease-19 (COVID-19) demands mental health concerns on the affected population. We examine the time-course shift of psychological burden among suspected and confirmed COVID-19 patients.Entities:
Keywords: COVID-19; Emotional distress; Holistic medicine; Mental health
Mesh:
Year: 2021 PMID: 33715927 PMCID: PMC7908863 DOI: 10.1016/j.jfma.2021.02.014
Source DB: PubMed Journal: J Formos Med Assoc ISSN: 0929-6646 Impact factor: 3.282
Clinical characteristics of 109 patients admitted for suspected or confirmed COVID-19 stratified by presence of psychological distress.
| Characteristics | Psychological distress upon hospital admission | ||||||
|---|---|---|---|---|---|---|---|
| All | None | Presence | |||||
| 0–5 points | ≥6 points | ||||||
| n = 109 | n = 91 (83.49) | n = 18 (16.51) | |||||
| Excluded | 105 | (96.33) | 88 | (96.70) | 17 | (94.44) | 0.520 |
| Confirmed | 4 | (3.67) | 3 | (3.30) | 1 | (5.56) | |
| Mean, SD | 5.39, | 6.69 | 5.29, | 6.78 | 5.89, | 6.35 | 0.728 |
| mean, sd | 37.06, | 18.22 | 37.95, | 18.51 | 32.61, | 16.42 | 0.258 |
| <30 | 48 | (44.04) | 36 | (39.56) | 12 | (66.67) | 0.096 |
| 30–59 | 45 | (41.28) | 40 | (43.96) | 5 | (27.78) | |
| ≥60 | 16 | (14.68) | 15 | (16.48) | 1 | (5.56) | |
| 0.278 | |||||||
| Female | 49 | (44.95) | 43 | (47.25) | 6 | (33.33) | |
| Male | 60 | (55.05) | 48 | (52.75) | 12 | (66.67) | |
| Mean, SD | 24.05, | 5.55 | 24.29, | 5.75 | 22.83, | 4.32 | 0.311 |
| Underweight | 11 | (10.09) | 8 | (8.79) | 3 | (16.67) | 0.875 |
| Normal | 50 | (45.87) | 42 | (46.15) | 8 | (44.44) | |
| Overweight | 21 | (19.27) | 18 | (19.78) | 3 | (16.67) | |
| Hypertension | 17 | (15.60) | 15 | (16.48) | 2 | (11.11) | 0.733 |
| Dyslipidemia | 10 | (9.17) | 9 | (9.89) | 1 | (5.56) | 1.000 |
| COPD/asthma | 10 | (9.17) | 8 | (8.79) | 2 | (11.11) | 0.669 |
| Diabetes mellitus | 8 | (7.34) | 8 | (8.79) | 0 | (0.00) | 0.348 |
| Coronary artery disease | 4 | (3.67) | 4 | (4.40) | 0 | (0.00) | 1.000 |
| Malignancy | 3 | (2.75) | 3 | (3.30) | 0 | (0.00) | 1.000 |
| Atrial fibrillation | 2 | (1.83) | 1 | (1.10) | 1 | (5.56) | 0.304 |
| Chronic viral hepatitis | 2 | (1.83) | 2 | (2.20) | 0 | (0.00) | 1.000 |
| Autoimmune disease | 2 | (1.83) | 1 | (1.10) | 1 | (5.56) | 0.304 |
| Old cerebral vascular accident | 1 | (0.92) | 1 | (1.10) | 0 | (0.00) | 1.000 |
| Chronic kidney disease | 1 | (0.92) | 0 | (0.00) | 1 | (5.56) | 0.165 |
| Idiopathic pulmonary fibrosis | 1 | (0.92) | 1 | (1.10) | 0 | (0.00) | 1.000 |
| Cough | 76 | (69.72) | 67 | (73.63) | 9 | (50.00) | 0.046 |
| Pneumonia | 57 | (52.29) | 49 | (53.85) | 8 | (44.44) | 0.466 |
| Fever or chills | 56 | (51.38) | 47 | (51.65) | 9 | (50.00) | 0.898 |
| Sore throat | 37 | (33.94) | 29 | (31.87) | 8 | (44.44) | 0.303 |
| Rhinitis | 36 | (33.03) | 31 | (34.07) | 5 | (27.78) | 0.604 |
| Shortness of breath | 18 | (16.51) | 14 | (15.38) | 4 | (22.22) | 0.493 |
| Muscle ache | 15 | (13.76) | 13 | (14.29) | 2 | (11.11) | 1.000 |
| Malaise | 14 | (12.84) | 9 | (9.89) | 5 | (27.78) | 0.054 |
| Others | 15 | (13.76) | 12 | (13.19) | 3 | (16.67) | 0.711 |
| Diarrhea | 5 | (4.59) | 3 | (3.30) | 2 | (11.11) | 0.190 |
| Headache | 5 | (4.59) | 4 | (4.40) | 1 | (5.56) | 1.000 |
| Nausea or vomiting | 4 | (3.67) | 4 | (4.40) | 0 | (0.00) | 1.000 |
| Chest pain | 3 | (2.75) | 2 | (2.20) | 1 | (5.56) | 0.421 |
| Anorexia | 2 | (1.83) | 1 | (1.10) | 1 | (5.56) | 0.304 |
| Arthralgia | 1 | (0.92) | 1 | (1.10) | 0 | (0.00) | 1.000 |
| Taste changes | 1 | (0.92) | 0 | (0.00) | 1 | (5.56) | 0.165 |
| Olfactory dysfunction | 0 | (0.00) | 0 | (0.00) | 0 | (0.00) | |
| 0.582 | |||||||
| Overseas traveling | 74 | (67.89) | 61 | (67.03) | 13 | (72.22) | |
| Contact history | 27 | (24.77) | 24 | (26.37) | 3 | (16.67) | |
| Others | 8 | (7.34) | 6 | (6.59) | 2 | (11.11) | |
| 0.148 | |||||||
| Service industry | 30 | (27.52) | 27 | (29.67) | 3 | (16.67) | |
| Student | 17 | (15.60) | 14 | (15.38) | 3 | (16.67) | |
| Office staff | 9 | (8.26) | 9 | (9.89) | 0 | (0.00) | |
| Manufacturing industry | 8 | (7.34) | 4 | (4.40) | 4 | (22.22) | |
| Healthcare | 5 | (4.59) | 5 | (5.49) | 0 | (0.00) | |
| Tourism | 4 | (3.67) | 3 | (3.30) | 1 | (5.56) | |
| Other | 12 | (11.01) | 11 | (12.09) | 1 | (5.56) | |
| None | 24 | (22.02) | 18 | (19.78) | 6 | (33.33) | |
SD, standard deviation, COPD; chronic obstructive pulmonary disease.
By Fisher exact test.
Risk factors for psychological distress upon hospital admission (adapted 5-item brief symptom rating scale ≥6 points) among 109 patients with suspected or confirmed COVID-19.
| Psychological distress | Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Cohort | n | (%) | OR | (95% Wald CL) | aOR | (95% Wald CL) | |||
| Excluded | 105 | 17 | (16.19) | 1 | |||||
| Confirmed | 4 | 1 | (25.00) | 1.73 | (0.17, 17.59) | 0.645 | |||
| Female | 49 | 6 | (12.24) | 1 | |||||
| Male | 60 | 12 | (20.00) | 1.79 | (0.62, 5.19) | 0.282 | |||
| <30 | 48 | 12 | (25.00) | 1 | |||||
| 30–59 | 45 | 5 | (11.11) | 0.38 | (0.12, 1.17) | 0.091 | |||
| ≥60 | 16 | 1 | (6.25) | 0.20 | (0.02, 1.68) | 0.138 | |||
| Normal | 50 | 8 | (16.00) | 1 | |||||
| Underweight | 11 | 3 | (27.27) | 1.97 | (0.43, 9.07) | 0.385 | |||
| Overweight | 21 | 3 | (14.29) | 0.88 | (0.21, 3.68) | 0.856 | |||
| Obese | 27 | 4 | (14.81) | 0.91 | (0.25, 3.36) | 0.891 | |||
| No | 77 | 13 | (16.88) | 1 | |||||
| Yes | 32 | 5 | (15.63) | 0.91 | (0.30, 2.81) | 0.872 | |||
| No | 92 | 16 | (17.39) | 1 | |||||
| Yes | 17 | 2 | (11.76) | 0.63 | (0.13, 3.05) | 0.569 | |||
| No | 99 | 17 | (17.17) | 1 | |||||
| Yes | 10 | 1 | (10.00) | 0.54 | (0.06, 4.51) | 0.566 | |||
| No | 99 | 16 | (16.16) | 1 | |||||
| Yes | 10 | 2 | (20.00) | 1.30 | (0.25, 6.68) | 0.756 | |||
| January–February | 51 | 5 | (9.80) | 1 | 1 | ||||
| March | 43 | 8 | (18.60) | 2.10 | (0.63, 6.99) | 0.225 | 2.43 | (0.68, 8.70) | 0.172 |
| April–May | 15 | 5 | (33.33) | 4.60 | (1.12, 18.95) | 0.035 | 7.66 | (1.46, 40.28) | 0.016 |
| No | 33 | 9 | (27.27) | 1 | 1 | ||||
| Yes | 76 | 9 | (11.84) | 0.36 | (0.13, 1.01) | 0.052 | 0.25 | (0.08, 0.81) | 0.021 |
| No | 52 | 10 | (19.23) | 1 | |||||
| Yes | 57 | 8 | (14.04) | 0.69 | (0.25, 1.90) | 0.467 | |||
| No | 53 | 9 | (16.98) | 1 | |||||
| Yes | 56 | 9 | (16.07) | 0.94 | (0.34, 2.57) | 0.898 | |||
| No | 72 | 10 | (13.89) | 1 | 1 | ||||
| Yes | 37 | 8 | (21.62) | 1.71 | (0.61, 4.79) | 0.307 | 4.24 | (1.17, 15.29) | 0.028 |
| No | 73 | 13 | (17.81) | 1 | |||||
| Yes | 36 | 5 | (13.89) | 0.74 | (0.24, 2.28) | 0.605 | |||
| No | 91 | 14 | (15.38) | 1 | |||||
| Yes | 18 | 4 | (22.22) | 1.57 | (0.45, 5.48) | 0.478 | |||
| No | 94 | 16 | (17.02) | 1 | |||||
| Yes | 15 | 2 | (13.33) | 0.75 | (0.15, 3.65) | 0.722 | |||
| No | 95 | 13 | (13.68) | 1 | 1 | ||||
| Yes | 14 | 5 | (35.71) | 3.50 | (1.01, 12.11) | 0.048 | 5.24 | (1.21, 22.77) | 0.027 |
| No | 94 | 15 | (15.96) | 1 | |||||
| Yes | 15 | 3 | (20.00) | 1.32 | (0.33, 5.24) | 0.696 | |||
| Overseas traveling | 74 | 13 | (17.57) | 1 | |||||
| Contact history | 27 | 3 | (11.11) | 0.59 | (0.15, 2.24) | 0.436 | |||
| Others | 8 | 2 | (25.00) | 1.56 | (0.28, 8.64) | 0.608 | |||
OR, odds ratio; CL, confidence limits; aOR, adjusted odds ratio; COPD, chronic obstructive pulmonary disease.
The trend of psychological distress at hospital admission, discharge and outpatient follow-up for 108 patients with suspected or confirmed COVID-19.
| Parameter | Estimated value | Std err | 95% confidence interval | Z | Pr > |Z| | ||
|---|---|---|---|---|---|---|---|
| Time | Hospital admission | 0 | |||||
| Time | Hospital discharge | −1.5354 | 0.2724 | −2.0692 | −1.0016 | −5.64 | <0.0001 |
| Time | Follow-up | −2.4001 | 0.2903 | −2.9691 | −1.8312 | −8.27 | <0.0001 |
| Intercept | 2.7064 | 0.3174 | 2.0844 | 3.3284 | 8.53 | <0.0001 | |
Figure 1The 5-item brief symptom rating scale (BSRS-5) of 109 patients of suspected or confirmed COVID-19 at admission, before discharge, and during outpatient follow-up.